Gray-Market Retatrutide: Real-World Data Show Half the Weight Loss and More Cardiovascular Risk
TL;DR: Gray-market retatrutide users lost half the trial-level weight but kept its elevated cardiovascular and neuropsychiatric symptom risk.
What Did the New Gray-Market Retatrutide Study Find?
A retrospective cohort study built from de-identified electronic health records, reported by Medscape on 26 August 2026, compared outcomes among people using compounded or direct-to-consumer ("gray-market") retatrutide against patients enrolled in Eli Lilly's controlled clinical trials, and against matched real-world users of the two approved incretin drugs, semaglutide and tirzepatide.[1] The headline finding cuts against the assumption that gray-market product simply delivers a cheaper version of the same trial-level effect: patients using compounded or direct-to-consumer retatrutide lost roughly 7.2% of body weight at 6–12 months, versus 15.5% in the study's own matched trial-arm cohort over a comparable window — while still carrying a materially higher burden of new-onset cardiovascular and neuropsychiatric symptoms than either approved comparator drug.[1]
The study sits alongside a rapidly growing body of research-adjacent reporting on unapproved retatrutide use, including a separate medRxiv preprint analysing self-reported symptoms among Reddit users of unapproved retatrutide, which similarly found a symptom profile diverging from the gastrointestinal-dominated pattern seen in Lilly's own Phase 2 and Phase 3 programme.[2]
Preprint findings, not a peer-reviewed final result. As reported, this is a preprint cohort analysis. Relative-risk estimates from EHR-derived, non-randomised comparator groups are hypothesis-generating and can be confounded by differences in why patients sought each drug, not proof that any single ingredient caused a given symptom.
How Was the Study Designed?
Researchers adjudicated de-identified clinical notes and flagged 983 patients whose records mentioned retatrutide by name. Of those, exposure was confirmed in 652 patients (66.3%), and a traceable supply route was documented for 531 (54%).[1] Among the patients with a documented route, 378 (71.2%) had obtained purported retatrutide entirely outside of clinical trial participation — most commonly through online or telehealth vendors (57.4%) or compounding pharmacies (29.4%).[1]
After matching, the final analytic sample comprised 89 trial-arm patients and 243 direct-to-consumer patients, compared against 890 matched semaglutide initiators and 890 matched tirzepatide initiators drawn from the same EHR network.[1] Matched baseline characteristics were closely balanced across arms: mean age approximately 51 years, roughly 63% women, mean BMI approximately 33, and around 37.1% with documented prior incretin-drug exposure.[1]
Reported by Medscape, 26 August 2026, citing a preprint cohort analysis.
Separately, the underlying analysis found that nontrial use of product purported to be retatrutide grew roughly 1.8-fold per quarter between October 2023 and March 2026 — a growth curve consistent with the retail and telehealth expansion documented in earlier reporting on unapproved sales through websites, clinics and even convenience stores.[1][3]
How Much Weight Loss Did Gray-Market Users Actually See?
The comparison the study draws out most sharply is between labelled intent and measured outcome. Despite being sold and used as "retatrutide," the compounded/direct-to-consumer cohort's weight-loss trajectory tracked closely with matched tirzepatide users rather than with the trial-arm retatrutide cohort:
| Cohort | n | Body-weight change (6–12 mo) |
|---|---|---|
| Trial-arm retatrutide (matched) | 89 | −15.5% |
| Compounded / direct-to-consumer retatrutide | 243 | −7.2% |
| Matched tirzepatide initiators | 890 | −7.7% |
Note that the 15.5% trial-arm figure reflects this study's own 6–12 month EHR-linked window for a small (n=89) subgroup, and is not directly comparable to Lilly's published 80-week TRIUMPH-1 topline result of up to 28–30% weight loss, which used a longer follow-up and a formally randomised, controlled protocol — see our TRIUMPH-1 coverage for that dataset. What the table above does establish is an internal comparison within one analysis: gray-market product, whatever it actually contained, did not reproduce the effect size of retatrutide dosed under trial conditions, and instead performed in line with an entirely different, already-approved molecule.
Were Gray-Market Users at Higher Risk of Side Effects?
Yes, on the relative-risk estimates reported. The pooled retatrutide cohort (trial-arm and compounded users combined) showed a significantly higher rate of new-onset symptoms than either approved-drug comparator group, including a 56% higher relative risk of cardiovascular symptoms (RR 1.56) and a 95% higher relative risk of neuropsychiatric symptoms (RR 1.95) versus matched semaglutide and tirzepatide users.[1] In practice, that means gray-market users retained retatrutide's characteristic heart-rate elevation and broader symptom signal even though their weight-loss outcome undershot the trial-level effect — the least favourable combination the data could show: reduced apparent benefit alongside a maintained or amplified risk signal.[1]
The authors describe the findings as hypothesis-generating, in keeping with the limits of a non-randomised, EHR-derived comparison, but frame them as warranting pharmacovigilance attention given the scale and growth rate of nontrial use documented in the same analysis.[1]
Why the Gap Between Labelled Product and Trial-Level Results?
This study did not test product samples for identity or purity, so it cannot say precisely what the 243 direct-to-consumer patients actually injected. But the pattern it describes lines up with what Eli Lilly's own litigation has already documented: in six federal lawsuits filed in August 2026 against sellers of "research use only"-labelled retatrutide, Lilly said laboratory testing of seized vials found dosages ranging from zero active ingredient to overdose levels, and in some cases an entirely different active ingredient, including insulin.[4] A vial sold as retatrutide, outside any verified chain of custody, is not confirmed to contain retatrutide at any specific concentration — and the real-world outcomes data above are one of the first attempts to quantify what that uncertainty looks like in aggregate, across hundreds of patients, rather than in a single seized-product test.
1. Lilly's clinical trial supply
Retatrutide administered under randomised, controlled conditions with verified dosing — the only channel producing the 15–30% weight-loss range reported in Lilly's own Phase 3 TRIUMPH programme.
2. Gray-market / direct-to-consumer sales (this study)
Product sold via online vendors, telehealth or compounding pharmacies with no FDA evaluation of identity, purity or dosing accuracy — the channel associated with roughly half the trial-level weight loss and a higher symptom burden.
3. Research-use reagents (what Velox Peptides supplies)
Retatrutide manufactured and HPLC-verified strictly as an in vitro laboratory reagent for qualified researchers, sold with batch documentation, and never represented as approved, sterile, or fit for human administration.
What Should UK Researchers Take From This?
The cohort described in this study is a US, EHR-linked patient population using product for direct human administration — it has no equivalent status under UK law, where the Human Medicines Regulations 2012 already prohibit supplying an unlicensed medicine for human use, and retatrutide holds no marketing authorisation anywhere. Nothing in this reporting changes retatrutide's published pharmacology or its Phase 3 trial data; it is a real-world outcomes study of how an experimental molecule performs, and what risks it carries, once it is diverted into unverified direct-to-consumer channels rather than administered under trial-grade quality control.
For UK-based researchers, the distinction this site has made consistently across its retatrutide coverage still holds: a research reagent supplied with batch-level HPLC verification, sold explicitly for laboratory use and never represented as a finished drug product, sits in an entirely different category from an unverified vial sold to a patient for self-injection with no chain of custody. The outcomes data reported here concern the latter.
Retatrutide reference material is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Medscape. Gray-Market Retatrutide: Less Weight Loss, More CV Effects. 26 August 2026. medscape.com
- medRxiv. Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide. Sehgal, Tronieri, Rader, Ungar et al. Posted 3 June 2026. medrxiv.org
- Velox Peptides. Retatrutide Black-Market Sales Trigger a Poison Center Surge. See our poison-centre data guide for the earlier US retail investigation.
- Velox Peptides. Why Is Eli Lilly Suing Six “Research Use Only” Retatrutide Sellers? See our black-market lawsuits guide for Lilly's seized-product testing findings.
Frequently Asked Questions
What did the new gray-market retatrutide study find?
A retrospective cohort study using de-identified electronic health records, reported by Medscape on 26 August 2026, found that patients using compounded or direct-to-consumer ("gray-market") retatrutide lost roughly half the body weight seen in a matched trial-arm cohort at 6-12 months (7.2% vs 15.5%), while the pooled retatrutide group (trial plus compounded) showed a significantly higher rate of new-onset cardiovascular and neuropsychiatric symptoms than matched semaglutide and tirzepatide comparators.
How was the study designed?
Researchers adjudicated de-identified clinical notes from 983 patients whose records mentioned retatrutide, confirming exposure in 652 (66.3%) and documenting a traceable supply route for 531 (54%). Of those, 378 (71.2%) obtained purported retatrutide outside of clinical trial participation, mostly via online or telehealth vendors (57.4%) or compounding pharmacies (29.4%). The final matched analysis compared 89 trial-arm patients and 243 direct-to-consumer patients against 890 matched semaglutide and 890 matched tirzepatide initiators.
Why did gray-market users lose less weight than trial participants?
The study did not test product purity directly, but the gap lines up with separate findings from Eli Lilly's own litigation: laboratory testing of seized "retatrutide" vials found incorrect dosages ranging from zero active ingredient to overdose levels, and in some cases entirely wrong active ingredients, including insulin. A gray-market vial labelled retatrutide is not verified to contain retatrutide at any specific concentration.
Were gray-market users at higher risk of side effects?
Yes. The pooled retatrutide cohort (trial and compounded users combined) showed a significantly higher new-onset symptom burden than matched semaglutide and tirzepatide comparators, including a higher relative risk of cardiovascular symptoms (RR 1.56) and neuropsychiatric symptoms (RR 1.95). Gray-market users retained retatrutide's characteristic heart-rate elevation despite achieving less weight loss than trial participants.
Does this affect Velox Peptides' research-grade retatrutide supply?
No. This study concerns patients using product obtained for direct human use through unregulated online, telehealth or compounding channels, tracked through clinical records. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent, with batch-level documentation, for use by qualified researchers — never as a consumer product and never represented as approved or fit for human administration.